However, the authors concluded that the myotrophic effect of IGF-1 might be adversely affected by insulin resistance, so therapeutic interventions for dysregulated glucose metabolism in SMA should target insulin resistance. This evidence concerns the gene IGF1 and proximal spinal muscular atrophy.